Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) VP Jeffrey T. L. Smith sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $31.14, for a total transaction of $93,420.00. Following the completion of the transaction, the vice president now owns 3,000 shares in the company, valued at approximately $93,420. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) opened at 30.20 on Friday. The firm’s market cap is $1.52 billion. The company’s 50 day moving average is $32.28 and its 200-day moving average is $28.38. Alder BioPharmaceuticals Inc. has a 52-week low of $15.82 and a 52-week high of $39.43.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.04. The company earned $0.11 million during the quarter, compared to the consensus estimate of $1.14 million. During the same period last year, the firm earned ($0.46) EPS. The business’s quarterly revenue was up 112900.0% compared to the same quarter last year. On average, equities analysts predict that Alder BioPharmaceuticals Inc. will post ($3.33) EPS for the current fiscal year.

Insider Buying and Selling by Quarter for Alder BioPharmaceuticals (NASDAQ:ALDR)

A number of large investors have recently added to or reduced their stakes in ALDR. BNP Paribas Arbitrage SA increased its stake in Alder BioPharmaceuticals by 110.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,844 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 2,016 shares during the last quarter. Birchview Capital LP acquired a new stake in Alder BioPharmaceuticals during the second quarter valued at approximately $129,000. Teacher Retirement System of Texas increased its stake in Alder BioPharmaceuticals by 85.5% in the second quarter. Teacher Retirement System of Texas now owns 5,393 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,485 shares during the last quarter. Legal & General Group Plc increased its stake in Alder BioPharmaceuticals by 57.6% in the first quarter. Legal & General Group Plc now owns 8,349 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 3,053 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in Alder BioPharmaceuticals during the second quarter valued at approximately $206,000.

A number of research analysts have recently issued reports on ALDR shares. Jefferies Group restated a “buy” rating on shares of Alder BioPharmaceuticals in a research report on Tuesday, August 23rd. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a research report on Tuesday, September 27th. Finally, Brean Capital started coverage on shares of Alder BioPharmaceuticals in a research report on Friday, September 30th. They issued a “buy” rating and a $45.00 price target on the stock. Seven analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus target price of $45.00.

Alder BioPharmaceuticals Company Profile

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

5 Day Chart for NASDAQ:ALDR

Receive News & Stock Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related stocks with our FREE daily email newsletter.